All In Biotech

Drug Trial Radar · NCT06380751

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 788 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

788

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Dec 18, 2029

Study completion Dec 30, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

Conditions

  • Advanced Breast Cancer

Interventions

  • Saruparib (AZD5305)Drug

    Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.

  • CamizestrantDrug

    Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .

  • AbemaciclibDrug

    CDK4/6 Inhibitor

  • RibociclibDrug

    CDK4/6 Inhibitor

  • PalbociclibDrug

    CDK 4/6 Inhibitor

  • FulvestrantDrug

    Endocrine Therapy

  • LetrozoleDrug

    Endorcine Therapy

  • AnastrozoleDrug

    Endocrine Therapy

  • ExemestaneDrug

    Endocrine Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (Arm 1 vs arm 2)Time frame: Up to approximately 64 months

Locations

306 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona · Recruiting

  • Research Site

    Fountain Valley, California · Recruiting

  • Research Site

    Glendale, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Newport Beach, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Grand Junction, Colorado · Withdrawn

  • Research Site

    Hollywood, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Orlando, Florida · Withdrawn

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Arlington Heights, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Evanston, Illinois · Recruiting

  • Research Site

    Park Ridge, Illinois · Withdrawn

  • Research Site

    Schaumburg, Illinois · Not yet recruiting

  • Research Site

    Urbana, Illinois · Recruiting

  • Research Site

    Winfield, Illinois · Recruiting

  • Research Site

    Indianapolis, Indiana · Withdrawn

  • Research Site

    Louisville, Kentucky · Withdrawn

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Silver Spring, Maryland · Withdrawn

  • Research Site

    Silver Spring, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Dearborn, Michigan · Withdrawn

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Royal Oak, Michigan · Withdrawn

  • Research Site

    Royal Oak, Michigan · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Saint Joseph, Missouri · Recruiting

  • Research Site

    Springfield, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Camden, New Jersey · Recruiting

  • Research Site

    New Brunswick, New Jersey · Withdrawn

  • Research Site

    Brooklyn, New York · Withdrawn

  • Research Site

    Mineola, New York · Recruiting

  • Research Site

    New Hyde Park, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

Showing 40 of 306 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.